Abbott registers EXACT-VT trial testing DuoVT PFA system for ventricular tachycardia
Abbott Medical Devices is recruiting for a single-arm study of its DuoVT pulsed field ablation system in patients with sustained ventricular tachycardia or frequent PVCs.
Abbott's only item logged in the registry this period concerns a new ablation device study for ventricular arrhythmias.
- The study, titled "Evaluation of the DuoVT PFA System for Ventricular Tachycardia" (NCT07706712, acronym EXACT-VT), is a prospective, non-randomized, single-arm, multicenter study to evaluate the safety and effectiveness of the DuoVT Pulsed Field Ablation (PFA) System.1 It is sponsored by Abbott Medical Devices1 and is currently recruiting1 with an actual start date of 2026-09-291 and estimated enrollment of 50 participants1. The trial targets patients with sustained monomorphic ventricular tachycardia (SMMVT) or frequent premature ventricular complexes (PVCs)1, and its primary safety endpoint tracks the proportion of subjects experiencing one or more predefined Primary Safety Adverse Events determined to be definitely related to the device and/or procedure, with onset within 7 days of the index ablation procedure1. The record was first posted on 2026-07-16, per the source's own posting date.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.